Women with pulmonary arterial hypertension (PAH) secondary to congenital heart disease (PAH-CHD) are at a high risk of heart failure, pulmonary hypertensive crisis, or even death during pregnancy, a study reports. Those at a higher risk appeared to be women with…
News
With an estimated 1.37 billion inhabitants, India will likely surpass China in five years as the world’s most populous country. That also means it will have more rare-disease patients than any nation. It already has more than twice as many as the 28-member European Union. Harsha K. Rajasimha, a genomics…
Levels of NT-proBNP can predict long-term outcomes and response to treatment with Uptravi (selexipag) in patients with pulmonary arterial hypertension (PAH), a post-hoc analysis of the Phase 3 GRIPHON trial shows. The study, “Association of NT-proBNP and Long-Term Outcome in Patients with Pulmonary Arterial Hypertension: Insights from the Phase III…
Despite having better heart function and less severe disease, patients with a lung disease underlying their pulmonary hypertension (PH) have survival rates that are as poor as those with idiopathic PH, a study suggests. The study, “Outcomes of Lung Disease-Associated Pulmonary Hypertension and Impact of Elevated Pulmonary Vascular Resistance,”…
The heart’s ventricular mass may be an early prognostic biomarker for predicting the risk of heart failure and death in people with pulmonary arterial hypertension (PAH), a recent study suggests. The research, “Ventricular mass…
As they have for the past five years, members of the pulmonary hypertension (PH) community are preparing to participate in PHenomenal Hope 5K, an event established to raise disease awareness and research funds for Team PHenomenal Hope. Held this year on April 27, the flat-course event will begin and…
Patients with pulmonary hypertension (PH) living in the U.K. experience delayed diagnosis, which has important implications for their financial and emotional status, according to a survey conducted by the Pulmonary Hypertension Association UK (PHA-UK). The results were described in an article, titled…
Myth 1: If you can’t run with the big dogs, stay on the porch. Truth: In the words of the late great Dr. Martin Luther King Jr., “if you can’t fly then run, if you can’t run then walk, if you can’t walk then crawl, but whatever you do you…
The health regulatory agency for Australia has approved Mallinckrodt Pharmaceuticals‘ INOmax (nitric oxide) gas for inhalation as a treatment for adult patients with perioperative pulmonary hypertension (PH) in combination with cardiovascular (heart) surgery. INOmax is a vasodilator inhalation device that works by widening and relaxing blood vessels…
United Therapeutics announced it has ended its Phase 3 BEAT trial testing esuberaprost as an add-on therapy to its product Tyvaso (inhaled treprostinil) for clinically symptomatic patients with pulmonary arterial hypertension (PAH). According to a company press release, the study failed to reach its main endpoint of delaying the…
The U.S. Food and Drug Administration (FDA) has agreed to change the ongoing Phase 2b study evaluating INOpulse in patients with pulmonary hypertension (PH) associated with interstitial lung disease (PH-ILD) into a Phase 2/3 clinical trial, the therapy’s manufacturer, Bellerophon Therapeutics, announced. With this decision the agency also agreed to change the…
Combined therapy with Revatio (sildenafil) and Opsumit (macitentan) was effective in a patient diagnosed with pulmonary hypertension (PH) associated with a rare blood disorder called polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome, a case report shows. The…
